Human multiple myeloma is an incurability of haematological cancer with recurrence rates above 90%. For the successful use of chemotherapy in MM, the critical limiting factor is the severe adverse effects of this drug. The anticancer efficiency of Losmapimod encapsulated in poly(lactic-co-glycolic acid) nanoparticles (LOS@PLGA-NPs) in vitro using multiple myeloma cells has been established. Furthermore, the morphological examination, hydrodynamic size and zeta potential of the nanoparticle were examined by the high-resolution transmission electron microscopy and dynamic light scattering method. The Cell Counting Kit-8 analysis has shown a significant inhibitory impact of LOS@PLGA-NPs on MM cancer cells (U266 and IM9). Furthermore, an investigation of the mechanism showed that apoptosis in cancer cells has performed by anticancer activity. We also demonstrated that such drugs showed promise antimetastatic efficacy and inhibited cancer cell invasiveness. Importantly, LOS@PLGA-NPs have confirmed to indicate that the dramatically better animal safety profile of the LOS is highlighted as prospective candidates for MM cancer treatment using these LOS@PLGA-NPs and deserve further evaluation.

人类多发性骨髓瘤是一种无法治愈的血液癌症，复发率超过 90%。对于 MM 成功使用化疗，关键的限制因素是该药物的严重不良反应。使用多发性骨髓瘤细胞在体外封装在聚（乳酸-乙醇酸共聚物）纳米颗粒（LOS@PLGA-NPs）中的 Losmapimod 的抗癌效率已经确定。此外，通过高分辨率透射电子显微镜和动态光散射方法检查了纳米颗粒的形态学检查、流体动力学尺寸和 zeta 电位。Cell Counting Kit-8 分析显示 LOS@PLGA-NPs 对 MM 癌细胞（U266 和 IM9）具有显着的抑制作用。此外，对该机制的研究表明，癌细胞的凋亡是通过抗癌活性进行的。我们还证明，此类药物显示出良好的抗转移功效并抑制癌细胞侵袭。重要的是，LOS@PLGA-NPs 已证实表明 LOS 显着更好的动物安全性被强调为使用这些 LOS@PLGA-NPs 治疗 MM 癌症的潜在候选者，值得进一步评估。